Clinical Trial Update: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain [Phase 3]

View source ↗

Summary

Phase IIIB/Phase 3 study evaluating capivasertib in combination with fulvestrant for advanced breast cancer in patients who relapsed or progressed on endocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capivasertib (capivasertib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING